|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SPARC correlates with unfavorable outcome and promotes tumor growth in lung squamous cell carcinoma.
|
31233732 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
For all tumour subsets, α-SMA and osteonectin scored significantly higher in the stroma > parenchyma whilst α-SMA was overexpressed along the tumour invasive front > centre (p<0.05).
|
31262562 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SPARC depletion reduces tumor dissemination that significantly prolongs survival and improves response to cytostatic therapy.
|
31062076 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SPARC and TUBB3 IHC was performed on the tumor biopsy tissues which were obtained from patients before treatment.
|
30643929 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our earlier studies highlighted the tumour-suppressor effect of secreted protein acidic and rich in cysteine (SPARC) in OvCa through multi-faceted roles inhibiting cancer cell interactions within the peritoneal milieu.
|
30765860 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, the expression levels of SPARC and LRG1 correlated with tumour sidedness and were predictive of tumour recurrence.
|
31753726 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Methods:</b> To investigate the role of SPARC on HSA accumulation in tumors, we compared HSA uptake in U87MG glioblastoma cells with different SPARC expression.
|
31695779 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, stromal SPARC had a pro-metastatic impact in vitro and was a characteristic of aggressive tumors with poor prognosis in CRC patients.
|
31554208 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SPARC positive patients undergoing disease monitoring are more likely to develop tumor relapse (age and gender Adj.
|
30632279 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It also exhibited greater tumor accumulation and tumor penetration via gp60- and SPARC-mediated biomimetic transport than THP and AN-THP.
|
31479235 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High expression of nuclear YAP1 in tumor stroma was significantly correlated with SPARC expression and fibrosis degree in human PDAC tissues.
|
31352078 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using LC-MS/MS, we show that SPARC dependent collagen deposition does not affect intratumoural gemcitabine accumulation or immediate therapeutic response in tumour bearing KC-SPARC<sup>WT</sup> and KC-SPARC<sup>-/-</sup>mice.
|
31597597 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Treatment with HSA-ICG-DDP NPs induced generation of reactive oxygen species (ROS) and cytotoxicity in SPARC-highly expressed tumor and CAFs.
|
31603446 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Stromal SPARC expression was analyzed by immunohistochemistry on tumor tissue microarrays (TMAs) from the patients.
|
30719160 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Higher SPARC expression was correlated with poorer tumor differentiation, poorer WPOI pattern, and significantly and shorter overall survival.
|
30706473 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our findings suggest that SPARC overexpression promotes tumor growth, inducing epithelial-mesenchymal transition and acquisition of a stem cell phenotype.
|
31041810 |
2019 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
SPARC is down-regulated by DNA methylation and functions as a tumor suppressor in T-cell lymphoma.
|
29277504 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumour size was a significant predictor of serum osteonectin.
|
29756486 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Soluble factors related to proficient tumor-stroma cross-talk are detectable in plasma of primary lung cancer patients and may represent a valuable complementary diagnostic tool to discriminate lung cancer patients from healthy heavy-smokers individuals as shown for the SPARC protein.
|
30227835 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
N-cadherin, Snail1, and secreted protein acidic and rich in cysteine (SPARC) immunoreactivity was observed in 8%, 62%, and 38% of tumors, respectively.
|
30544617 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Correction: Chang, C.-H.; et al. Secreted Protein Acidic and Rich in Cysteine (SPARC) Enhances Cell Proliferation, Migration, and Epithelial Mesenchymal Transition, and SPARC Expression Is Associated with Tumor Grade in Head and Neck Cancer. <i>Int. J. Mol. Sci.</i> 2017, <i>18</i>, 1556.
|
30096877 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Patients with SPARC expression in tumor stroma but not in cancer cells had poorer progression-free survival compared with those with negative SPARC expression in tumor stroma cells (3.3 vs. 5.0 months, P = 0.036).
|
28304139 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of SPARC and VEGF were significantly correlated with tumor histological types, invasion depth, differentiation and lymph node metastasis of patients (p<0.05).
|
29077165 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results suggest that SPARC treatment enhances the EMT signaling pathway via activation of AKT, and exogenous SPARC and tumor expressing SPARC might be associated with tumor progression in head and neck cancers.
|
28718842 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The survival of patients with ESCC was not associated with the expression level of SPARC protein (P>0.05), but was associated with the tumor location (P<0.05), differentiation (P<0.001) and staging (P<0.05).
|
28713937 |
2017 |